Agentix Corp. (AGTX)
USD 0.05
(-35.88%)
USD 0.05
(-35.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 261.39 Thousand USD | 0.0% |
| 2021 | 292.75 Thousand USD | 314684.95% |
| 2020 | 93.00 USD | 0.0% |
| 2018 | 2265.00 USD | -68.06% |
| 2017 | 7092.00 USD | 451.05% |
| 2016 | 1287.00 USD | -92.65% |
| 2015 | 17.52 Thousand USD | -87.44% |
| 2014 | 139.52 Thousand USD | 74.41% |
| 2013 | 80 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 330.5 Thousand USD | 26.44% |
| 2023 Q4 | 261.39 Thousand USD | 134.48% |
| 2023 FY | 261.39 Thousand USD | 0.0% |
| 2023 Q1 | 11.02 Thousand USD | -83.72% |
| 2023 Q2 | 8535.00 USD | -22.56% |
| 2023 Q3 | 111.47 Thousand USD | 1206.09% |
| 2022 Q4 | 67.71 Thousand USD | 33.62% |
| 2022 Q3 | 50.67 Thousand USD | -1.04% |
| 2022 Q2 | 51.2 Thousand USD | -11.42% |
| 2022 Q1 | 57.8 Thousand USD | 13.7% |
| 2021 FY | 292.75 Thousand USD | 314684.95% |
| 2021 Q1 | 17.00 USD | 30.77% |
| 2021 Q2 | 292.75 Thousand USD | 1721958.82% |
| 2021 Q3 | 61.08 Thousand USD | -79.13% |
| 2021 Q4 | 50.84 Thousand USD | -16.77% |
| 2020 FY | 93.00 USD | 0.0% |
| 2020 Q1 | 64.00 USD | -93.66% |
| 2020 Q2 | 93.00 USD | 45.31% |
| 2020 Q3 | 61.00 USD | -34.41% |
| 2020 Q4 | 13.00 USD | -78.69% |
| 2019 Q3 | 3050.00 USD | 34.66% |
| 2019 Q2 | 2265.00 USD | 195.69% |
| 2019 Q4 | 1010.00 USD | -66.89% |
| 2019 Q1 | 766.00 USD | -59.04% |
| 2018 Q3 | 9865.00 USD | 39.1% |
| 2018 Q4 | 1870.00 USD | -81.04% |
| 2018 FY | 2265.00 USD | -68.06% |
| 2018 Q1 | 11.24 Thousand USD | -4.53% |
| 2018 Q2 | 7092.00 USD | -36.92% |
| 2017 Q3 | 25.71 Thousand USD | 1898.21% |
| 2017 FY | 7092.00 USD | 451.05% |
| 2017 Q1 | 2028.00 USD | -81.59% |
| 2017 Q2 | 1287.00 USD | -36.54% |
| 2017 Q4 | 11.77 Thousand USD | -54.21% |
| 2016 Q4 | 11.01 Thousand USD | 4.23% |
| 2016 Q2 | 17.52 Thousand USD | -52.86% |
| 2016 FY | 1287.00 USD | -92.65% |
| 2016 Q1 | 37.16 Thousand USD | -18.45% |
| 2016 Q3 | 10.56 Thousand USD | -39.68% |
| 2015 Q4 | 45.57 Thousand USD | -40.03% |
| 2015 FY | 17.52 Thousand USD | -87.44% |
| 2015 Q3 | 75.99 Thousand USD | -45.53% |
| 2015 Q2 | 139.52 Thousand USD | 0.0% |
| 2014 FY | 139.52 Thousand USD | 74.41% |
| 2013 FY | 80 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -11215.671% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 86.651% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 97.523% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 52.657% |
| Rebus Holdings, Inc. | 5000.00 USD | -5127.84% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.799% |
| Qrons Inc. | 420.00 USD | -62136.19% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 66.081% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.065% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 45.606% |
| Skye Bioscience, Inc. | 11.94 Million USD | 97.811% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.327% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 96.379% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -242.342% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.756% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 81.747% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -261.213% |
| Mesoblast Limited | 667.9 Million USD | 99.961% |
| Marizyme, Inc. | 22.01 Million USD | 98.813% |
| Genus plc | 1.02 Billion USD | 99.975% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 80.757% |
| Pharming Group N.V. | 462.85 Million USD | 99.944% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 92.11% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 47.621% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 58.311% |
| ContraFect Corporation | 20.67 Million USD | 98.736% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 33.039% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 31.604% |
| IMV Inc. | 31.33 Million USD | 99.166% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 93.695% |
| MultiCell Technologies, Inc. | 126.22 USD | -206992.378% |
| ONE Bio Corp. | 70.08 Million USD | 99.627% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 72.183% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.797% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 39.453% |
| Q BioMed Inc. | 3.51 Million USD | 92.565% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.257% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -0.044% |
| Biomind Labs Inc. | 73.81 Thousand USD | -254.099% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.941% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 81.959% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.129% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 90.482% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 61.979% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 89.959% |
| GB Sciences, Inc. | 103.44 Thousand USD | -152.694% |
| Alpha Cognition Inc. | 2.45 Million USD | 89.34% |
| HST Global, Inc. | 1526.00 USD | -17029.227% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 73.542% |
| Halberd Corporation | 10.13 Thousand USD | -2480.12% |
| Enzolytics Inc. | 361.7 Million USD | 99.928% |
| Resverlogix Corp. | 8.11 Million USD | 96.779% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 86.08% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.452% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 59.136% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1047.412% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 97.079% |
| AVAX Technologies, Inc. | 7.37 Million USD | 96.457% |
| Zenith Capital Corp. | 7410.00 USD | -3427.557% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.992% |
| Ember Therapeutics, Inc. | 184.00 USD | -141960.87% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 18.773% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -0.011% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 71.832% |
| Kadimastem Ltd | 2.3 Million USD | 88.655% |
| Helix BioMedix, Inc. | 3.02 Million USD | 91.359% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.504% |
| BioStem Technologies, Inc. | 14.56 Million USD | 98.205% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -357.827% |
| LadRx Corporation | 2.3 Million USD | 88.674% |
| Cell Source, Inc. | 195.17 Thousand USD | -33.93% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 26.08% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 26.08% |
| NovAccess Global Inc. | 62.24 Thousand USD | -319.92% |
| Affymax, Inc. | 7.44 Million USD | 96.488% |
| Itoco Inc. | 1.4 Million USD | 81.33% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -173.26% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -146.596% |
| Mobile Lads Corp. | 52.00 USD | -502576.923% |
| CytoDyn Inc. | 11.13 Million USD | 97.653% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -82.827% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1361.924% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 32.189% |
| SYBLEU INC | 330.46 Thousand USD | 20.902% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 36.156% |
| International Stem Cell Corporation | 5.39 Million USD | 95.15% |
| Bioxytran, Inc. | 137.63 Thousand USD | -89.913% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 98.258% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.423% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -230.876% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 69.77% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 96.523% |
| Neutra Corp. | 2851.00 USD | -9068.432% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.193% |
| PureTech Health plc | 693.97 Million USD | 99.962% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 96.761% |
| IXICO plc | 15.84 Million USD | 98.35% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 96.844% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.747% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.922% |